NCT04890028Completed
Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases
Detection and Metabolic Characterization in DOPA PET/CT of no Treated Brain Metastases of Lung Cancer, Breast Cancer and Melanoma
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
About 20 to 30% of patients treated for cancer will have brain metastases. These brain metastases are found more frequently in patients with lung cancer, breast cancer or melanoma. The prognosis of these patients is unfavorable but prolonged survival can be obtained with the local and systemic treatments currently available. Brain MRI is the gold standard for evaluating brain metastases but has limitations in therapeutic evaluation, partially offset by PET imaging of amino acid metabolism. Our work aims to compare the performance of PET-DOPA with standard MRI for the detection of brain metastases (≥ 5mm) in lung cancer, breast cancer and melanoma; and to characterize these lesions using dynamic acquisitions obtained with a digital PET camera with high spatial resolution. Having better knowledge of the metabolic characteristics of newly discovered brain metastases, the objective of subsequent studies will be to better assess the per- or post-therapeutic efficacy of radiotherapy and the various systemic therapies available (chemotherapy, targeted therapy, immunotherapy).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 12 May 2021
- Start date
- 3 Dec 2021
- Primary completion date
- 3 Dec 2025
- Lead sponsor
- Institut Cancerologie de l'Ouest
- Diseases
- Melanoma, Lung cancer
- NCT number
- NCT04890028
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 3 Dec 2021 to the primary completion date, 3 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the realization of DOPA PET/CT,
Other illness
- History of irradiation cerebral
- History of brain surgery for brain metastasis or glial tumor
- Other concomitant cancer, or history of cancer in the 5 years preceding the performance of DOPA PET/CT
- Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.
- Disorder precluding understanding of trial information or informed consent.
Other
- New anti-tumor treatment started between the discovery of brain metastases and the performance of DOPA PET/CT
- Pregnant or lactating females
Who the study is looking for
- Primitive cancer (brest cancer, lung cancer, melanoma) proven histologically
- Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm
- Age \> 18 years
- Patient has valid health insurance
- Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancerologie de L'Ouest Coordinator of this site? Confirm its status | Angers | France | Unknown status |
| CHU Angers Coordinator of this site? Confirm its status | Angers | France | Unknown status |
| Institut de Cancérologie de l'Ouest Coordinator of this site? Confirm its status | Saint-Herblain | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.